The evolving role of Alemtuzumab in management of patients with CLL

S. Faderl, S. Coutré, J. C. Byrd, C. Dearden, Alex Denes, M. J S Dyer, S. A. Gregory, J. G. Gribben, P. Hillmen, M. Keating, S. Rosen, P. Venugopal, K. Rai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.

Original languageEnglish (US)
Pages (from-to)2147-2152
Number of pages6
JournalLeukemia
Volume19
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
alemtuzumab
Guidelines

Keywords

  • Alemtuzumab
  • CLL therapy
  • Minimal residual disease
  • Patient management
  • Treatment guidelines

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Faderl, S., Coutré, S., Byrd, J. C., Dearden, C., Denes, A., Dyer, M. J. S., ... Rai, K. (2005). The evolving role of Alemtuzumab in management of patients with CLL. Leukemia, 19(12), 2147-2152. https://doi.org/10.1038/sj.leu.2403984

The evolving role of Alemtuzumab in management of patients with CLL. / Faderl, S.; Coutré, S.; Byrd, J. C.; Dearden, C.; Denes, Alex; Dyer, M. J S; Gregory, S. A.; Gribben, J. G.; Hillmen, P.; Keating, M.; Rosen, S.; Venugopal, P.; Rai, K.

In: Leukemia, Vol. 19, No. 12, 12.2005, p. 2147-2152.

Research output: Contribution to journalArticle

Faderl, S, Coutré, S, Byrd, JC, Dearden, C, Denes, A, Dyer, MJS, Gregory, SA, Gribben, JG, Hillmen, P, Keating, M, Rosen, S, Venugopal, P & Rai, K 2005, 'The evolving role of Alemtuzumab in management of patients with CLL', Leukemia, vol. 19, no. 12, pp. 2147-2152. https://doi.org/10.1038/sj.leu.2403984
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJS et al. The evolving role of Alemtuzumab in management of patients with CLL. Leukemia. 2005 Dec;19(12):2147-2152. https://doi.org/10.1038/sj.leu.2403984
Faderl, S. ; Coutré, S. ; Byrd, J. C. ; Dearden, C. ; Denes, Alex ; Dyer, M. J S ; Gregory, S. A. ; Gribben, J. G. ; Hillmen, P. ; Keating, M. ; Rosen, S. ; Venugopal, P. ; Rai, K. / The evolving role of Alemtuzumab in management of patients with CLL. In: Leukemia. 2005 ; Vol. 19, No. 12. pp. 2147-2152.
@article{1c754ee6387f4d17b97bbfd9d464f73a,
title = "The evolving role of Alemtuzumab in management of patients with CLL",
abstract = "New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.",
keywords = "Alemtuzumab, CLL therapy, Minimal residual disease, Patient management, Treatment guidelines",
author = "S. Faderl and S. Coutr{\'e} and Byrd, {J. C.} and C. Dearden and Alex Denes and Dyer, {M. J S} and Gregory, {S. A.} and Gribben, {J. G.} and P. Hillmen and M. Keating and S. Rosen and P. Venugopal and K. Rai",
year = "2005",
month = "12",
doi = "10.1038/sj.leu.2403984",
language = "English (US)",
volume = "19",
pages = "2147--2152",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The evolving role of Alemtuzumab in management of patients with CLL

AU - Faderl, S.

AU - Coutré, S.

AU - Byrd, J. C.

AU - Dearden, C.

AU - Denes, Alex

AU - Dyer, M. J S

AU - Gregory, S. A.

AU - Gribben, J. G.

AU - Hillmen, P.

AU - Keating, M.

AU - Rosen, S.

AU - Venugopal, P.

AU - Rai, K.

PY - 2005/12

Y1 - 2005/12

N2 - New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.

AB - New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.

KW - Alemtuzumab

KW - CLL therapy

KW - Minimal residual disease

KW - Patient management

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=28544440832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544440832&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403984

DO - 10.1038/sj.leu.2403984

M3 - Article

VL - 19

SP - 2147

EP - 2152

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -